SLC7A5/LAT1 Antibody - Azide and BSA Free

Immunohistochemistry-Paraffin: SLC7A5/LAT1 Antibody [NB100-734] - Left: primary breast cancer tumor; Right: normal breast tissue.

Product Discontinued

SLC7A5/LAT1 Antibody - Azide and BSA Free Summary

• Immunogen: KLH conjugated synthetic peptide (RHRKPEL) representing aa 419-425 of Human LAT1.
• Localization: Integral Membrane Protein
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: SLC7A5
• Purity: IgG purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5 ug/ml
  • Immunohistochemistry-Paraffin 5 ug/ml

Packaging, Storage & Formulations

• Storage: Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: No Preservative
• Concentration: 1.9 mg/ml
• Purity: IgG purified

Alternate Names for SLC7A5/LAT1 Antibody - Azide and BSA Free

• 4F2 LC
• 4F2LC
• CD98
• CD98lc
• D16S469EL-type amino acid transporter 1
• E16
• Integral membrane protein E16
• large neutral amino acids transporter 1
• large neutral amino acids transporter small subunit 1
• LAT1
• LAT1hLAT1
• MPE16
• MPE16CD98 light chain
• SLC7A5
• sodium-independent neutral amino acid transporter LAT1,4F2LC
• solute carrier family 7 (cationic amino acid transporter, y+ system), member 5,4F2 light chain
• Solute carrier family 7 member 5
• TA1
• y+ system cationic amino acid transporter

Background

Mammalian cells have several amino acid transport systems. These systems have been defined by both activity and specific genes. L-type amino acid transporter 1 (LAT1) is a 12 membrane-spanning protein. LAT1 is a Na + -independent neutral amino acid transporter agency and essential for the transporter of large neutral amino acid such as Leucine, Isoleucine, and Valine through the plasma membrane. LAT1 has been proposed to be one of the major nutrient transport systems at the blood-brain barrier. Drugs such as L Dopa are transported by LAT1. LAT1 is thought to be up-regulated to support the high protein synthesis for cell growth in some tumor cell lines.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for SLC7A5/LAT1 Antibody (NB100-734)(4)

Publications using NB100-734

• Sekine M, Koh I, Nakamoto K et al. Selective Inhibition of L-type Amino Acid Transporter 1 Suppresses Cell Proliferation in Ovarian Clear Cell Carcinoma Anticancer research 2023-06-01 [PMID: 37247931] (IHC)
• Sawazaki H, Arai Y, Ito Y Et al. Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer Research and reports in urology 2021-08-21 [PMID: 34458203] (IF/IHC, Human)
• Sato K, Miyamoto M, Takano M, Tsuda H Correlation of high LAT1 expression with the prognosis of endometrioid carcinoma of the uterine corpus Virchows Arch. 2020-03-06 [PMID: 32144539] (IF/IHC)
• Sato K, Miyamoto M, Takano M et al. Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma. Virchows Arch. 2019-01-13 [PMID: 30637450] (IHC-P, Human)

Bioinformatics

• Gene Symbol: SLC7A5
• Entrez:
  • 8140(Human)
• Uniprot:
  • Q01650()